Natco Pharma Spins Off Agrochemicals Unit to Boost Pharma Focus

Natco Pharma's agrochemicals turnover was ₹60.62 crore in FY25, representing 1.48% of its total revenue. The company's board has approved a plan to demerge this business to sharpen its focus on core pharmaceutical operations.

The Deal Details

Natco Pharma Limited's Board of Directors approved a Scheme of Arrangement on March 24, 2026, to transfer its Agrochemicals Business to Natco Crop Health Sciences Limited, a wholly-owned subsidiary. The plan is for the agrochemicals business to operate as a going concern within this new entity.

Under the scheme, shareholders will receive one fully paid-up equity share of INR 2 in Natco Crop Health Sciences for every one fully paid-up equity share of INR 2 they hold in Natco Pharma. The demerger is slated to be effective from October 1, 2026.

In separate decisions, the company also plans to establish a new subsidiary in Nigeria with an investment of up to USD 100,000 and liquidate its Australian subsidiary.

Strategic Rationale

This strategic move aims to separate Natco Pharma's distinct business lines – Pharmaceuticals and Agrochemicals. The goal is to provide dedicated management focus, enable independent capital allocation, and allow for specialized growth strategies in each segment. By creating two distinct companies, Natco Pharma expects to better highlight the value of each business and potentially attract a wider range of investors.

The parent company, Natco Pharma, will retain a 20% stake in Natco Crop Health Sciences to provide strategic oversight and support.

Background: Prioritizing Pharmaceuticals

Natco Pharma has been strategically emphasizing its pharmaceutical business, concentrating on complex generics, first-to-file opportunities, and niche therapeutic areas, especially in the US market. An example of this focus is the recent launch of its Semaglutide injection in India for type 2 diabetes.

The agrochemicals business, while established, accounts for a smaller part of Natco's overall revenue, contributing just 1.48% in FY25. This demerger will allow the company to direct more resources and strategic attention toward its high-growth pharmaceutical segments.

What Shareholders Can Expect

Shareholders will receive one new share in the demerged Natco Crop Health Sciences Limited for each share they own in Natco Pharma. This separation could lead to different investment opportunities in the pharmaceutical and agrochemical sectors. Natco Pharma will continue its primary focus on pharmaceuticals, while Natco Crop Health Sciences will operate independently in the agrochemical market.

Approval Hurdles and Regulatory Risks

The entire demerger plan requires approvals from shareholders and creditors of both companies, along with sanction from the National Company Law Tribunal (NCLT). Any failure to secure these approvals could delay or prevent the scheme from proceeding.

Additionally, Natco Pharma faces ongoing regulatory scrutiny. Its API facility in Chennai has received seven FDA Form-483 observations, and its Kothur facility has a warning letter from the US FDA. These issues present potential compliance challenges and could impact its supply to the US market.

Competitive Landscape

Natco Pharma's main strength is its pharmaceutical segment. It competes with major players like Sun Pharma, India's largest pharmaceutical company, and Cipla, which has a global presence. Dr. Reddy's Laboratories is also a competitor, with both Dr. Reddy's and Natco pursuing Semaglutide approvals for diabetes. Sun Pharma and Zydus, meanwhile, are targeting broader indications, including obesity, showing the competitive dynamics in new drug launches. The demerged agrochemical entity will enter a sector with established companies such as UPL and PI Industries.

Key Next Steps

Investors will be closely watching the progress of obtaining all necessary regulatory approvals from shareholders, creditors, and the NCLT. The successful and timely implementation of the scheme by the October 1, 2026, Appointed Date will be critical. Following the demerger, investors will track the performance and strategic direction of both Natco Pharma (pharmaceuticals) and Natco Crop Health Sciences (agrochemicals).